NASH Companies Take The Stage At AASLD
AASLD Round-Up: NGM, Inventiva, Albireo Among The Companies Progressing In NASH
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.
